{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:08:26Z","timestamp":1780574906515,"version":"3.54.1"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201510003B"],"award-info":[{"award-number":["HHSF223201510003B"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To explore how boxed warning (BW) information fits within the context of prescribers' overall treatment decision\u2010making and communication with patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In\u2010depth interviews (<jats:italic>N<\/jats:italic>\u2009=\u200952) were conducted with primary care providers and specialists. Participants were presented with one of two prescribing scenarios: (1) estrogen vaginal inserts to treat vulvovaginal atrophy (VVA) associated with menopause; or (2) direct\u2010acting antivirals (DAA) to treat chronic hepatitis C virus infection (HCV). The semi\u2010structured interviews explored participants' treatment decision\u2010making within the scenario, reactions to current prescribing information for a product within the FDA\u2010approved drug class, as well as their perceptions of BWs generally.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Across scenarios, providers described that the BW is only one of several factors that influence treatment decision\u2010making. In the VVA scenario, symptom severity, family history, and experience with nonprescription drugs were raised as common factors that influence prescribing considerations; compared to comorbid infections, viral load, and HCV genotype in the HCV scenario. Perceptions of the DAA BW were generally positive or neutral, as many participants found the information important and appropriate. The VVA BW was viewed less favorably, with many participants stating the BW overstates the risk for this drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Findings suggest that BWs are one of several factors that influence providers' treatment decisions, and BW influence largely depends on context. Providers across scenarios expressed notable differences in their perceptions of the risk information provided in the presented BWs; however, across scenarios participants expressed consideration of how patients may perceive the BW.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5766","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:20:55Z","timestamp":1709180455000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescriber perceptions of boxed warnings: A qualitative study"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6413-0320","authenticated-orcid":false,"given":"Rachel N.","family":"Ingersoll","sequence":"first","affiliation":[{"name":"Fors Marsh, Health Communication Research  Arlington Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0709-7293","authenticated-orcid":false,"given":"Elise T.","family":"Bui","sequence":"additional","affiliation":[{"name":"Fors Marsh, Health Communication Research  Arlington Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2419-683X","authenticated-orcid":false,"given":"Blair","family":"Coleman","sequence":"additional","affiliation":[{"name":"Office of Program and Strategic Analysis (OPSA), Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4608-6850","authenticated-orcid":false,"given":"Esther H.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eggers","sequence":"additional","affiliation":[{"name":"Office of Program and Strategic Analysis (OPSA), Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"e_1_2_14_2_1","volume-title":"Guidance for Industry\u2014Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products\u2014Content and Format","author":"U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)","year":"2011"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602972"},{"key":"e_1_2_14_4_1","unstructured":"MartinCB HalesCM GuQ OgdenCL.Prescription Drug Use in the United States 2015\u20132016.2019."},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2320"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1948"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13469"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.593523"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6273"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12561"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744\u2010023\u201000581\u2010x"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31826c86f1"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1011042"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1193"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.4065\/82.4.518"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913\u2010021\u201006103\u20101"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318245a160"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3480"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010018\u20105181\u20106"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2014.05.140039"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2021.07.028"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5073"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181\u2010015\u20100519\u20103"},{"key":"e_1_2_14_24_1","unstructured":"Food and Drug Administration.Labeling Lower\u2010Dose Estrogen\u2010Alone Products for Symptoms of Vulvar and Vaginal Atrophy.https:\/\/www.federalregister.gov\/documents\/2015\/09\/28\/2015\u201024509\/labeling\u2010lower\u2010dose\u2010estrogen\u2010alone\u2010products\u2010for\u2010symptoms\u2010of\u2010vulvar\u2010and\u2010vaginal\u2010atrophy"},{"key":"e_1_2_14_25_1","unstructured":"National Library of Medicine.LABEL: HARVONI\u2010Ledipasvir and Sofosbuvir Tablet Film Coated. DailyMed.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075"},{"key":"e_1_2_14_26_1","unstructured":"National Library of Medicine.LABEL: MAVYRET\u2010Glecaprevir and Pibrentasvir Tablet Film Coated. DailyMed.2017."},{"key":"e_1_2_14_27_1","unstructured":"National Library of Medicine.LABEL: ZEPATIER\u2010Elbasvir and Grazoprevir Tablet Film Coated. DailyMed.2018."},{"key":"e_1_2_14_28_1","unstructured":"International Q.NVIVO (version 11).http:\/\/download.qsrinternational.com\/Document\/NVivo11\/11.3.0\/en\u2010US\/NVivo11\u2010Getting\u2010Started\u2010Guide\u2010Pro\u2010edition.pdf"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"issue":"5","key":"e_1_2_14_30_1","first-page":"360","article-title":"Understanding interobserver agreement: the kappa statistic","volume":"37","author":"Viera AJ","year":"2005","journal-title":"Fam Med"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002173"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15007"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081\u20101206(10)60529\u20107"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000316"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxad085"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T06:43:48Z","timestamp":1710571428000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/pds.5766"],"URL":"https:\/\/doi.org\/10.1002\/pds.5766","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"2023-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5766"}}